This HTML5 document contains 36 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n20http://linked.opendata.cz/resource/drugbank/drug/DB00106/identifier/guide-to-pharmacology/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00106/identifier/chebi/
n24http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00106/identifier/wikipedia/
n9http://www.rxlist.com/cgi/generic/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00106/identifier/pharmgkb/
n19http://linked.opendata.cz/resource/drugbank/patent/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/resource/drugbank/drug/DB00106/identifier/bindingdb/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n13http://www.drugs.com/cdi/
n10http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00106/identifier/kegg-drug/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00106/identifier/iuphar/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00106/identifier/drugbank/
n25http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00106
rdf:type
n3:Drug
n3:description
Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
n3:group
withdrawn approved investigational
n3:halfLife
13.2 ± 3.2 days
n3:indication
For palliative treatment of advanced prostate cancer.
n3:manufacturer
n4:271B45AB-363D-11E5-9242-09173F13E4C5
owl:sameAs
n12:DB00106 n24:DB00106
dcterms:title
Abarelix
adms:identifier
n6:50102442 n7:DB00106 n17:D02738 n18:Abarelix n20:1188 n21:337298 n22:1188 n23:PA164754915
n3:mechanismOfAction
Abarelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion.
n3:packager
n4:271B45A9-363D-11E5-9242-09173F13E4C5 n4:271B45AA-363D-11E5-9242-09173F13E4C5
n3:patent
n19:6423686 n19:5968895
n3:toxicity
The maximum tolerated dose of abarelix has not been determined. The maximum dose used in clinical studies was 150 mg. There have been no reports of accidental overdose with abarelix.
n15:hasAHFSCode
n16:10-00%20
n3:proteinBinding
96-99%
foaf:page
n9:plenaxis.htm n13:abarelix.html
n3:Molecular-Formula
n10:271B45AD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n10:271B45AC-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n25:L02BX01
n3:absorption
Following IM administration of 100 mg, abarelix is absorbed slowly with a mean peak concentration of 43.4 ng/mL observed approximately 3 days after the injection.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
183552-38-7
n3:category